AgeX Therapeutics, Inc.

About AgeX Therapeutics, Inc.

The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.

47 articles with AgeX Therapeutics, Inc.

AgeX Therapeutics to Present at Metabesity 2019

10/11/2019

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, PhD will deliver a presentation titled “The Age-Related Metabolic Program” as part of a session at Metabesity 2019, October 15-16 in Washington, DC.
AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference

9/9/2019

AgeX Therapeutics, Inc. announced that founder and CEO Michael D. West, Ph.D. is presenting at the 21st Annual Rodman & Renshaw Global Investment Conference at the New York Palace Hotel in New York City.
AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine

9/4/2019

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

8/14/2019

AgeX Therapeutics, Inc., a biotechnology company focused on the development of therapeutics for human aging, reported financial and operating results for the second quarter ended June 30, 2019.
Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors

8/5/2019

Dr. May, CEO of Canada’s Centre for Commercialization of Regenerative Medicine (CCRM), brings 20 years of sector knowledge, leadership experience, and extensive global industry and investor networks
AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research

7/9/2019

AgeX Therapeutics, Inc. announced that founder and CEO Michael D. West, Ph.D. will present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, from the Life Extension Advocacy Foundation (LEAF), July 11-12 at The Cooper Union in New York City.
AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

5/15/2019

AgeX Therapeutics, Inc. reported financial and operating results for the first quarter ended March 31, 2019.
AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute

5/1/2019

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity, an evening event from Aikora Health and Foresight Institute, on Wednesday, May 1, in San Francisco.
AgeX Therapeutics to Present at Master Investor Show 2019

4/5/2019

AgeX Therapeutics, Inc., a biotechnology company focused on therapeutics for human aging, announced that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday, April 6 in London, England.
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update

4/1/2019

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative cellular and regenerative therapeutics for diseases of old age, reported financial and operating results for the fourth quarter and year ended December 31, 2018.
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants

3/22/2019

AgeX Therapeutics, Inc., a biotechnology company focused on innovative therapeutics for human aging, announced that it has received $4.5 million from the exercise of AgeX common stock warrants.
AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany

3/21/2019

AgeX Therapeutics, Inc., a biotechnology company focused on innovative therapeutics for human aging, announced that the company will present in multiple sessions at Undoing Aging 2019, March 28-30 in Berlin, Germany.
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London

1/31/2019

Details of the company’s participation follows.
AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019

1/22/2019

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019, January 21 in Silicon Valley.
LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019

1/17/2019

LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced today that it will be presenting its novel whole genome sequencing (WGS) interpretation solutions at Precision Medicine World Conference 2019 in Silicon Valley, on January 22nd, as part of the Clinical and Research Tools Showcase.
AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

1/9/2019

AgeX Therapeutics, Inc. (NYSE American: AGE) announced today the publication of data relating to its cell therapy product candidate AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed scientific journal Stem Cell Research & Therapy.
AgeX Therapeutics to Present at Biotech Showcase 2019

1/2/2019

AgeX Therapeutics, Inc. today announced that it will present at Biotech Showcase, to be held January 7-9, 2019 in San Francisco, California.
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American

11/29/2018

Company’s Common Stock Listed Under Symbol “AGE”
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference

11/29/2018

AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018.
BioTime Announces Distribution of AgeX Therapeutics Shares

11/28/2018

Distribution to Commence Today at 5:00pm ET